Terran receives FDA clearance for MRI platform

Terran Biosciences has received U.S. Food and Drug Administration (FDA) clearance to market its NM-101 AI platform for the analysis of neuromelanin-sensitive MRI scans.

NM-101 is a cloud-based analysis platform designed to integrate into existing workflows at hospitals and imaging centers. The platform allows doctors to send neuromelanin MRI images to Terran directly through the hospital picture archiving and communication system and receive a full report back in under an hour, the company said.

Neuromelanin is a molecule associated with certain cell populations in the brain, with research suggesting it is a potential biomarker for neurological disorders such as Parkinson’s disease. NM-101 can provide neuroradiologists information useful in determining neuromelanin association as an adjunct to diagnosis, Terran said.